Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Harvard Apparatus Regenerative Technology, Inc. logo — HRGN is a bioengineering company that is developing next-gen...

Harvard Apparatus Regenerative Technology, Inc.

HRGN is a bioengineering company that is developing next-generation esophageal implants.

Founded 2012 United States Holliston, United States 13 employees Post Ipo Equity Total: $32.10M Biotechnology, Health Care +1

General Information

Company Name Harvard Apparatus Regenerative Technology, Inc.
Founded Year 2012
Location United States Holliston, United States +1
Founders / Decision Makers
Team member Team member
Employees 13
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Post Ipo Equity
Social

Get notified when Harvard Apparatus Regenerative Technology, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Harvard Apparatus Regenerative Technology, Inc.

Harvard Apparatus Regenerative Technology, Inc. (HRGN) is a bioengineering company founded in 2012. Their slogan, "HRGN is a bioengineering company that is developing next-generation esophageal implants." succinctly captures their mission. The company is based in the United States and operates within the Biotechnology and Health Care sectors. Their focus is on developing organ replacement therapies using cellular scaffolds and tissue engineering to restore organ function. The most recent investment in HRGN was a $6.00M Post-IPO Equity investment on 31 March 2023. This investment indicates continued confidence in the company's innovative approach to regenerative medicine. As the company progresses through its clinical stage, the level of interest from investors may further amplify, positioning HRGN for impactful growth and advancements in the field of regenerative medicine.

Taxonomy: bioengineering, esophageal implants, organ replacement therapies, cellular scaffolds, tissue engineering, regenerative medicine, stem cells, organ regeneration, esophageal replacement, cancer treatment, trauma recovery, birth defects, clinical stage, medical implants

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 15 Apr 2024
Post-IPO Equity •••••• - 31 Mar 2023
Post-IPO Equity •••••• - 13 May 2022
Post-IPO Equity •••••• - 08 Sep 2021
Post-IPO Equity •••••• - 18 Aug 2020

View All 11 Funding Rounds

Harvard Apparatus Regenerative Technology, Inc. Alternatives & Competitors

Harvard Apparatus Regenerative Technology, Inc. vs
EDmicBio Inc.
EDmicBio Inc. Korea South

Investigate your drug with 3D biomimicry 3D organ-on-a-chip. We can build a better future for human

Seed
3 employees
Information Technology
Harvard Apparatus Regenerative Technology, Inc. vs
XVIVO Abdominal
XVIVO Abdominal The Netherlands

We believe in an extended life of organs. Nobody should die waiting for a new organ.

Series Unknown
11 employees
Health Care
Harvard Apparatus Regenerative Technology, Inc. vs
Clinical Consulting Associates, Inc.
Clinical Consulting Associates, Inc. United States

Professional and flexible staffing and consulting solutions for OPOs and Tissue Banks

41 employees
Health Care

FAQ About Harvard Apparatus Regenerative Technology, Inc.

HRGN is a bioengineering company that is developing next-generation esophageal implants.
Harvard Apparatus Regenerative Technology, Inc. was founded in 2012.
Harvard Apparatus Regenerative Technology, Inc. is headquartered in Holliston, United States.
Harvard Apparatus Regenerative Technology, Inc. operates in the following industries: Biotechnology, Health Care, Medical Devices.
Harvard Apparatus Regenerative Technology, Inc. has approximately 13 employees.
Harvard Apparatus Regenerative Technology, Inc. has completed 11 funding rounds, raising a total of $32.10M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Harvard Apparatus Regenerative Technology, Inc. include EDmicBio Inc., XVIVO Abdominal, Clinical Consulting Associates, Inc., Mississippi Organ Recovery Agency, vitOrgan Arzneimittel GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Harvard Apparatus Regenerative Technology, Inc. and EDmicBio Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Harvard Apparatus Regenerative Technology, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes